Abstract:Background Neuropilin - 2 ( NRP2) is a high-affinity kinase-deficient receptor for vascular endothelial growth factor ( VEGF) and semaphorin 3F. We investigated its function in human colorectal cancers.Methods Immunohistochemistry and immunoblotting were used to assess NRP2 expression levels in colorectal tumors and colorectal cancer cell lines, respectively. HCT-116 colorectal cancer cells stably transfected with short hairpin RNA ( shRNAs) against NRP2 or control shRNAs were assayed for proliferation by the tetrazolium salt 3-( 4,5-dimethylthiazol-2-yl)- 2,5- diphenyltetrazolium bromide ( MTT) assay and for activation of the VEGFR1 pathway by immuno blotting. Soft agar assays, Annexin V staining, and Boyden chamber assays were used to examine anchorage-independent growth, apoptosis in response to hypoxia, and cell migration/ invasion, respectively, in HCT-116 transfectants. Tumor growth and metastasis were analyzed in mice ( groups of 10) injected with shRNA-expressing HCT-116 cells. The effect of in vivo targeting of NRP2 by small interfering RNA ( siRNA) on the growth of hepatic colorectal tumors derived from luciferase-expressing HCT-116 cells was assessed by measuring changes in bioluminescence and final tumor volumes. All statistical tests were two-sided.Results NRP2 expression was substantially higher in tumors than in adjacent mucosa. HCT-116 transfectants with reduced NRP2 levels had reduced VEGFR1 signaling, but proliferation was unchanged. Anchorage-independent growth, survival under hypoxic conditions, and motility/ invasiveness were also reduced. In vivo, HCT-116 transfectants with reduced NRP2 demonstrated decreased tumor growth, fewer metastases, and increased apoptosis compared with control cells. Hepatic colorectal tumors in mice treated with NRP2 siRNAs were statistically significantly smaller than those in mice treated with control siRNAs ( at 28 days after implantation, mean control siRNAs = 420 mm(3), mean NRP2 siRNAs = 36 mm(3), NRP2 vs control: difference = 385 mm(3), 95% confidence interval = 174 mm(3) to 595 mm(3), P =.005).Conclusion NRP2 on colorectal carcinoma cells is important for tumor growth and is a potential therapeutic target in human cancers where it is expressed.

Structure-activity relationship studies and biological properties evaluation of peptidic NRP-1 ligands: Investigation of N-terminal cysteine importance

Structure-activity relationship study of a small cyclic peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor interaction with Neuropilin-1

Urea-Peptide Hybrids as VEGF-A165/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties

Peptidomimetic inhibitors of the VEGF-A165/NRP-1 complex obtained by modification of the C-terminal arginine

Discovery of novel nonpeptide small-molecule NRP1 antagonists: Virtual screening, molecular simulation and structural modification

Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells

Chirality and Rigidity in Triazole-Modified Peptidomimetics Interacting with Neuropilin-1

Targeting VEGF–neuropilin Interactions: a Promising Antitumor Strategy

Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver

Targeting neuropilin-1 interactions is a promising anti-tumor strategy

Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Synthesis and Structure-Activity Relationships of Pyrazine-Pyridine Biheteroaryls As Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors.

VEGFA, B, C: Implications of the C-Terminal Sequence Variations for the Interaction with Neuropilins

A structure-based pharmacophore modelling approach to identify and design new neprilysin (NEP) inhibitors: An in silico-based investigation

Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.

Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide

Design and In Silico Evaluation of a Novel Cyclic Disulfide-Rich anti-VEGF Peptide as a Potential Antiangiogenic Drug

A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism